Nasdaq

Silo Pharma, Inc. Files Provisional Patent Application for SPC-15 Targeting Stress-Induced Psychiatric Disorders

Silo Pharma, Inc. announced the filing of a provisional patent application for its lead asset, SPC-15, aimed at treating stress-induced psychiatric disorders such as PTSD. The patent focuses on the ...
Nasdaq

Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action

Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...
Seeking Alpha

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage ...
Seeking Alpha

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today ...
Managingip.com

Pediatric extension of an SPC expected

Pediatric extension is not yet implemented in Norway but will probably be later this year. The instrument is still under discussion within the European Economic Area (EEA) and can only be implemented ...